Navigation Links
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Date:10/25/2007

- Third Trial to Utilize FDG-PET Imaging -

SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will soon initiate a third Phase II clinical trial for VIA-2291, its lead compound. VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The new trial design utilizes Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET) to measure the impact of VIA-2291 on reducing vascular inflammation in treated patients.

The Company plans to enroll approximately 50 patients following an acute coronary syndrome event into a 24 week randomized, double blind, placebo- controlled study. Endpoints in the study will include reduction in plaque inflammation as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation.

VIA is collaborating on the study with Michael Farkouh, M.D. and Zahi Fayad, Ph.D. of Mount Sinai Heart in New York City, and Ahmed Tawakol, M.D. of Massachusetts General Hospital in Boston.

"VIA-2291 could provide a novel approach to addressing inflammation in coronary artery disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "This trial is an excellent example of utilizing the benefits of new imaging technology to help accelerate the development of potentially break- through drugs. The use of state-of-the art FDG-PET imaging technology provides an ideal methodology for measuring the effect of VIA-2291 on reducing vascular inflammation in atherosclerosis."

L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... (OTC BB: SOTK.pk) completed its Fiscal Year on February ... approximately $12,000,000, an increase of 21% over last year,s ... approximately $1,200,000, an increase of more than 100% over ... of $1,000,000. Sono-Tek will release final audited results in ...
... Ill., March 5, 2012   Process Seals recently ... materials with a new white material specifically developed to ... pharmaceutical, food and beverage, and biotech industries. ... use in O-rings, molded parts and butterfly valve seals ...
Cached Medicine Technology:Sono-Tek Announces Record Year End Results 2Process Seals Develops White Hygienic Sealing Material for Pharmaceutical, Food and Beverage, and Biotech Applications 2
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting ... Rome, Italy and is hosted by the Salesian Pontifical ... a wide variety of topics such as ADHD, anxiety, ... in athletes. The scientific program will feature the latest ... allows clients to see what is going on in ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... - Company to Webcast Presentation at 9:30 a.m. ET on ... Corporation,(Nasdaq: SMTS ) is scheduled to participate in the ... 22, 2008 at the New York Hilton., Bruce J. ... presentation that will be webcast live on Wednesday,May 21, 2008 ...
... have used cough medicine for children younger than two ... effective for children in this age group, an Australia-first ... and Royal Childrens Hospital study, surveyed 325 parents at ... care centres about their use of over-the-counter medication for ...
... The International Association for Dental Research (IADR) ... winners of the annual IADR/GSK Innovation in Oral ... innovative oral care technologies that may maintain and ... Sharing the $225,000 unrestricted research grant, which is ...
... 2008 Canadian researchers have shown that an electric ... neurologic and neuropsychological symptoms in humans. , Following ... and behavioral aftereffects, such as memory loss and symptoms ... grant from Hydro-Qubec and conducted by clinicians from the ...
... 15, 2008 Physicians and dentists should collaborate to ... or may develop osteoporosis, say researchers in the cover ... the American Dental Association. , The authors of the ... the medical and dental literature to examine osteoporosis effect ...
... with ICG-Guided Therapy On Over 76,000+ ... ... 15 CardioDynamics (Nasdaq:,CDICD), the innovator and leader of Impedance ... today,announced the presentation of a significant independent ICG clinical study,at ...
Cached Medicine News:Health News:Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 2Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 3Health News:Electric shocks can cause neurologic and neuropsychological symptoms 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: